Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...

DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out. My ...

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to ...

Amgen AMGN announced the launch of a new direct-to-consumer (DTC) program called AmgenNow, which will offer significant discounts on its marketed drugs. The company has initiated this DTC program with ...